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Abstract: Uterine smooth muscle tumors of uncertain malignant potential (STUMPs) represent a
heterogeneous group of tumors that cannot be histologically diagnosed as unequivocally benign
or malignant. For this reason, many authors are working to obtain a better definition of diagnostic
and prognostic criteria. In this work, we analyzed the genomic and epigenomic profile of uterine
smooth muscle tumors (USMTs) in order to find similarities and differences between STUMPs,
leiomyosarcomas (LMSs) and leiomyomas (LMs), and possibly identify prognostic factors in this
group of tumors. Array-CGH data on 23 USMTs demonstrated the presence of a more similar
genomic profile between STUMPs and LMSs. Some genes, such as PRKDC and PUM2, with a
potential prognostic value, were never previously associated with STUMP. The methylation data
appears to be very promising, especially with regards to the divergent profile found in the sample
that relapsed, characterized by an overall CGI hypomethylation. Finally, the Gene Ontology analysis
highlighted some cancer genes that could play a pivotal role in the unexpected aggressive behavior
that can be found in some of these tumors. These genes could prove to be prognostic markers in
the future.
Keywords: uterine STUMP; array-CGH; copy number alterations; Genome Wide DNA Methylation
1. Introduction
According to the 2014 WHO, uterine smooth muscle tumors (USMTs) consist of a group
of histologically heterogeneous and clinically diverse diseases ranging from malignant
leiomyosarcoma (LMS) to benign leiomyoma (LM). In between the aforementioned, lies a
heterogeneous group of rare mesenchymal tumors that cannot be clearly categorized
as benign or malignant lesions. Uterine smooth muscle tumors of uncertain malignant
potential (STUMPs) do not meet benign variant or true malignancy criteria, due to their
variability in histologic appearance, immunohistochemical profile and clinical outcome [1].
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The unusual combination of findings generally renders STUMP diagnosis very difficult,
while the different criteria adopted by pathologists affect its accuracy [2].
Although the majority of patients with uterine STUMPs have good outcomes, un-
expected aggressive behavior can be found in some of the tumors [2]. Because of the
neoplasm’s rarity, the etiology, prognostic factors, clinical outcomes and recurrence risks of
these tumors are poorly defined [3]. Recently, a new classification of lesions according to
genomic complexity has been described [4].
In this work, we analyzed the genomic profile of 23 USMTs by array-comparative
genomic hybridization (array-CGH). In four samples the methylation profile was also
investigated in order to find similarities and differences between STUMPs, LMSs and LMs,
and possibly identify prognostic factors in this group of tumors.
2. Results
2.1. Pathologic Features
We performed an array-CGH analysis on 23 USMTs: 3 LMs, 14 STUMPs, 5 LMSs
and 1 undifferentiated sarcoma (US), derived from a total of 20 patients who underwent
first surgery between 1996 and 2013. The histological characteristics, the age at diagnosis
and the type of surgery are listed in Table 1 (see also the Materials and Methods section).
The median age at first diagnosis was 45.4 years old (ranging from 23 to 68).
Among the 14 STUMPs, 11/14 were primary tumors, of which four (STUMP1, STUMP3,
STUMP4 and STUMP5) subsequently relapsed in either another STUMP or undifferenti-
ated sarcoma (US) or LMS. For three patients it was possible to analyze both the primary
STUMP and its recurrence (patients 4, 5 and 6). Primary STUMPs of patients 8 and 9 and
relapsed tumor of patient 7 were not available. Among the LMSs, three were primary
(LMS2, LMS3 and LMS4), while two were relapsed tumors (LMS1 and LMS5).
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Table 1. Clinical features.
Patient Sample Histotype Age atDiagnosis Surgery Mitosis KI-67 Markers ER PgR p16 p53
1 LM1 Leiomyoma 28 n.a. 0 5% n.a. n.a. n.a. n.a. n.a.




<1 × 10 HPF 0 n.a. n.a. n.a. n.a. n.a.
3 LM3 Leiomyoma 40 n.a. 0 <5% n.a. n.a. n.a. n.a. n.a.
4
STUMP1 STUMP 56 n.a. 2 × 10 HPF 10% Actin 3+ neg. neg. neg. 2+
STUMP2 STUMP 59 n.a. 5 × 10 HPF 10% Actin 3+ neg. neg. neg. 3+
5
STUMP3 STUMP 47 n.a. 4–5 × 10HPF <1% Actin 2+ neg. neg. neg. neg.




14 × 10 HPF 20% Actin r.e. neg. neg. neg. 3+
6




30% 50% neg. 2+




neg. 60% neg. neg.
7
STUMP5 STUMP 26 n.a. 6-7 × 10 HPF 30% Actin 1+ neg. neg. neg. neg.
n.a. Leiomyosarcoma n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
8









90% 70% neg. 2+
9










50% neg. neg. neg.
10 STUMP8 STUMP 40 Myomectomy 9 × 10 HPF 30% Actin 1+ neg. 20% neg. 3+
11 STUMP9 STUMP 31 n.a. 1 × 50 HPF <1% Actin neg.,Desmin 2+ neg. 70% neg. neg.
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Table 1. Cont.
Patient Sample Histotype Age atDiagnosis Surgery Mitosis KI-67 Markers ER PgR p16 p53
12 STUMP10 STUMP 30 Myomectomy 4–6 × 10HPF <1% Actin 2+ 10% 70% neg. neg.





HPF <1% Actin neg. neg. 40% neg. r.e.





HPF <5% Actin 1+ neg. neg. neg. neg.





HPF <1% Actin 1+ neg. 50% neg. neg.
16 STUMP14 STUMP 34 laparothomy 0–1 × 10HPF 1%
Actin 3+,
Desmin 3+ 30% 80% neg. neg.




9 × 10 HPF 30% Actin 2+,Desmin 2+ 20% 90% neg. neg.
18 LMS3 Leiomyosarcoma 63 n.a. 15 × 10 HPF 10% Actin 1+ neg. neg. neg. 3+
19




Desmin 1+ neg. 30% neg. r.e.
n.a. Leiomyosarcoma 54 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
20
n.a. Leiomyosarcoma 68 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
LMS5 Leiomyosarcoma 73 n.a. 1 × 10 HPF <1% Actin 1+ 40% 60% r.e. r.e.
n.a. Leiomyosarcoma 77 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
ER: estrogen receptor, HPF: high power field, LM: leiomyoma, LMS: leiomyosarcoma, n.a.: not available, neg: negative immunohistochemistry, PgR: progesterone receptor, r.e.: rare elements, STUMP: smooth
muscle tumors of uncertain malignant potential, US: undifferentiated sarcoma (more information in the Materials and Methods section).
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2.2. Array-CGH Results
STUMP samples revealed a wide range of copy number alterations (CNAs), from 17
to 365, with a median value of 86.5 (Table 2).
Table 2. Array-CGH results.
Patient Sample Follow Up OS
CNAs
Total Gain Loss
1 LM1 NED 6 110 106 4
2 LM2 NED 12 123 114 9






















ALIVE 13STUMP6 116 108 8
9
n.a.
NED 8STUMP7 94 88 6
10 STUMP8 NED 14 88 80 8
11 STUMP9 ALIVE 9 82 81 1
12 STUMP10 n.a. 10 40 38 2
13 STUMP11 NED 18 97 97 0
14 STUMP12 NED 10 156 155 1
15 STUMP13 NED 16 85 81 4
16 STUMP14 NED 7 59 58 1
17 LMS2 ALIVE 8 204 194 10








AWDLMS5 23 166 148 18
n.a.
LM: leiomyoma, STUMP: smooth muscle tumors of uncertain malignant potential, LMS: leiomyosarcoma, US:
undifferentiated sarcoma, NED: no evidence of disease, AWT: alive with tumor, DOD: dead of disease, OS: overall
survival (years from the first tumor).
Two samples (STUMP3 and STUMP4) showed an exceptional number of CNAs (365
and 256 respectively). LMSs’ total number of CNAs ranged from 126 to 262, with a median
value of 199. The only US sample analyzed showed the least number of CNAs compared
to other sarcomas. Finally, LMs displayed an unexpected number of CNAs, ranging from
110 to 268, with a median value of 123. No statistically significant differences for the total
number of CNAs were observed among the groups. A CNAs plot by chromosome for each
patient is displayed in Figure S1.
Interestingly, combining these data with the follow-up status, we found that primary
STUMPs and primary LMS derived from patients with a worst prognosis (dead of disease,
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DOD) displayed a higher number of CNAs compared to patients’ samples with a good
prognosis (alive with or without disease) (Figure 1A). As shown in Table 2, all patients
with no evidence of disease (NED) had a longer disease.
ANOVA analysis performed on CNAs’ distribution within chromosomes in LMs,
STUMPs and LMSs revealed a statistically significant difference only in chromosome 17
(LMs vs. STUMPs, Tukey test p = 0.0004; Figure 1B). This difference was also retained
after splitting STUMPs in two different groups based on their ability to relapse (LMs
vs. relapsing STUMPs, Tukey test p = 0.01; LMs vs. not relapsing STUMPs, Tukey test
p = 0.0008, data not shown). No other differences were observed between the two groups
of STUMPs or between STUMPs and LMSs.
Figure 1. Array-CGH results. (A) Number of CNAs and follow-up status (Student t test p < 0.05). (B) CNAs’ distribution
within chromosomes in leiomyomas, STUMPs and leiomyosarcomas (LM vs. STUMPs, ANOVA and Tukey test p = 0.0004).
* statistically significant difference; - comparison between LM and STUMP
In order to decipher a possible common code between STUMPs and LMSs or between
STUMPs and LMs, we further searched among the numerous CNAs detected for those
shared among STUMPs and LMSs, or STUMPs and LMs (at least three samples, Table S1).
CNAs common to all histotypes were excluded because they were not useful for setting the
STUMP genomic profile (data not shown). For the same reason, CNAs shared only among
STUMPs were included in the analysis.
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Curiously, losses represented a little percentage of the observed CNAs (6.2%). The ma-
jority was exclusive; few were shared between two samples. Moreover, known cancer-
associated genes were not found (data not shown).
Despite the high number of CNAs, only seven were shared by LMs and STUMPs.
Conversely, STUMPs and LMSs shared 47 CNAs, in particular gain/amplification of the
regions containing cancer related genes as PRKDC (8q11.21; eight samples), MLL3 (7q36.1;
seven samples), ROCK2 (2p25.1; six samples), CTSB (8p23.1; six samples) and STAT2
(12q13.2; five samples) (Table S1 and Table 3). Interestingly, three out of four relapsing
STUMPs shared an amplification of chromosome 2p24.1 including PUM2 gene, which was
not identified in other samples.
Narrowing down the analysis to the relapsing STUMPs and LMSs, we found some shared
CNAs, especially in STUMP4 (the only relapsed in a LMS), including gain/amplification of
the regions encompassing STAG1 (3q22.2–22.3; four samples), RFC4 (3q27.3; four samples),
CCRN4L and ELF2 (4q31.1; three samples) (Table 3).
As the amplification of the BCL2 gene in primitive STUMPs and their correspond-
ing relapsed tumors have been previously reported [5], an analysis of BCL2 data was
performed, revealing copy number gain or amplification in 13 samples: one leiomyoma
(LM2), four primary STUMPs (STUMP10, STUMP11, STUMP12, STUMP13), two relaps-
ing STUMPs (STUMP3 and STUMP4), one relapsed STUMP (STUMP6), three primary
leiomyosarcomas (LMS2, LMS3 and LMS4) and two relapsed LMSs (LMS1 and LMS5)
(Table S1 and Table 3).
Table 3. Top nine CNAs shared between STUMPs and leiomyosarcomas (all copy number gains).
PRKDC MLL3 ROCK2 CTSB STAT2 STAG1 RFC4 CCRN4L,ELF2 PUM2 BCL2
STUMP2 +
STUMP3 + + + + + +
STUMP4 + + + + + + +
STUMP5 +
STUMP6 + +
STUMP7 + + +
STUMP9 +
STUMP10 +
STUMP11 + + +
STUMP12 + + +
STUMP13 + +
LMS1 + + + +
LMS2 + + + + +
LMS3 + + + + + + +
LMS4 + + + + +
LMS5 + + + + + + +
2.3. Promoter CpG Island Methylation
We evaluated the CpG island methylation status of four samples, two STUMPs
(STUMP4, STUMP8) and two LMSs (LMS1 and LMS2). STUMP8 and LMS2 were pri-
mary lesions that had not yet relapsed, while LMS1 was the relapse of STUMP4. The array
platform used in this study covers 27,800 CpG Island (CGIs) of the human genome and all
the data (percentages and frequencies) are referred to the total number of CGIs included
in the array. We calculated the percentages of unmethylated/methylated/undetermined
CGIs and we observed that STUMP4, the primary lesion that relapsed, had a divergent
methylation pattern compared to the other three samples (Figure 2A, p < 0.01 Student’s
t test). In particular, the percentage of methylated CGIs for all chromosomes in STUMP4
was significantly lower (p < 0.01, Chi square test) compared to the one observed in the
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other three samples, which presented similar percentages, around 50%, of methylated and
unmethylated CGIs (Figure 2B).
Figure 2. Methylation results. (A) Frequency of unmethylated (−) and methylated (+) CGIs for each sample. The methylation
status for each chromosome is reported. Mean values are indicated with black dashes. STUMP4 vs. other samples * p < 0.01,
Student’s t test. (B) Frequency of methylated CGI islands for each chromosome in each sample. STUMP4 vs. other samples
* p < 0.01, Chi-square test.
In order to perform a Gene Ontology (GO) analysis, we set up two lists of genes on the
basis of the promoter methylation status. The first list included the 667 genes which were
methylated, while the second one the 2220 genes that resulted unmethylated in all samples.
Cancer-related GO terms were grouped in different functional categories, as previously
described [6]. Each category was scored based on its own percentage of genes belonging
to that specific category and normalized to the total number of genes. ‘Metabolism’ and
‘transcription and gene expression’ were the most represented categories in both lists of
methylated and unmethylated genes. However, no statistically significant differences were
identified (data not shown).
We subsequently refined our analysis, limiting the GOgroups to ‘biological process’
aspects (see Materials and Methods section). The most significant GO-groups included
336 genes (p-value = 1.92 × 10−35) and 99 genes (p-value = 1.68 × 10−9) from the unmethy-
lated and methylated gene lists respectively. We found that gene associated GOterms such
as ‘transcription and gene expression’, ‘cell cycle’ and ‘cell signalling’ were detected in both
the unmethylated and methylated genes’ lists. Conversely, GOterms such as ‘transport’ and
‘DNA repair and chromatin remodeling’ and ‘development and morphogenesis’ and ‘cell
death and apoptosis’ were found almost exclusively in the unmethylated or methylated
group of genes, respectively.
Given the divergent distribution of CGI methylation percentages in STUMP4, we then
compared its methylation pattern to the one of the other three samples. We found that
943 unmethylated genes and 180 methylated genes were exclusive to STUMP4, suggesting
a specific methylation signature for this tumor. We restricted the analysis to ‘biological
process’ aspects observing that 236 of the unmethylated genes in the most significant GO-
group (p-value = 2.33 × 10−11) were mainly involved in ‘transcription and gene expression’,
‘metabolism’, ‘cell signaling’, ‘cell cycle’ and ‘cell death and apoptosis’ categories, as verified
in the previous analysis. Surprisingly, only four of the methylated genes were included
in the most significant GO-group (p-value = 0.00648) and were involved in ‘cytoskeleton
organization’. Furthermore, statistical analysis (chi-square test) revealed a significant
difference for some categories between STUMP4 and the other samples (Figure 3).
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Figure 3. Gene Ontology results. Percentage of unmethylated and methylated genes in GOgroups. * p < 0.05.
The analysis’ results allowed to speculate on the potential activated “cell signalling”
pathways among the samples. For example, IK beta kinase/NFK beta cascade was mainly rep-
resented in STUMP4’s exclusively unmethylated gene list, while the Wnt signalling pathway
was detected in the list of genes found to be methylated in all the samples (Table S2).
Afterwards, we focused on the different methylation patterns between the STUMP
primary lesion and its recurrence (STUMP4 vs. LMS1). In order to perform the Gene
Ontology analysis, we established two lists of genes. The first list included 628 genes,
which were found methylated in STUMP4 and unmethylated in LMS1. Conversely, in the
second list 2972 genes were reported resultingunmethylated in STUMP4 and methylated in
LMS1. As expected, ‘metabolism’ and ‘transcription and gene expression’ were the most
represented biological functions in both samples, but no statistically significant differences
were identified (data not shown). However, the percentage of unmethylated promoter CGIs
in the ‘Cell signalling’ category differed in the two samples: STUMP4 displayed 3.1% of
unmethylated genes (92/2972) compared to 9.2% (58/628) of LMS1 (p < 0.01, chi square test).
In conclusion, we may assume that Ras protein signal transduction, Wnt signalling pathway
and NFKbeta cascade were more involved in the primary lesion than in its respective
recurrence, being more represented in STUMP4 unmethylated promoters (Table 4).
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Table 4. Cell signaling Pathways with the related genes in STUMP4 and its recurrence LMS1.
Cell Signaling Pathway Genes with a SignificantGOterm






NDFIP1, MAP3K7IP2, PLK2, NDFIP2,
NLRC3, PPM1A, SECTM1, TRIM13,
IRAK1, TSPAN6, VAPA, TNFAIP3,
BIRK2, C9orf89, EDG2, GOLT1B,




CSNK2B, LRRFIP2, PYGO2, PORCN,
DKK1, FZD3, FZD6, FZD8, HBP1,













ARGEF2, PSD3, CENTB2, CENTD1,
GNB1, DOK3, EVI5, PSD4, RASSF1,
RASSF6, GBF1, DDEF1, DOK2,





Ras GTPase activity 15
TBC1D5, TBC1D8, TBC1D9,






The World Health Organization classifications indicate that uterine smooth muscle
tumors that cannot be histologically diagnosed as unequivocally benign or malignant
should be termed STUMP [7]. For this reason, many authors are working to obtain a better
definition of diagnostic and prognostic criteria. Several immunohistochemical markers
have been analyzed, as well as genetic alterations, but a definitive response has not been
obtained yet.
We reported an array-CGH analysis performed on 23 USMTs, including 14 STUMPs,
in order to extend the genomic knowledge on this type of tumor. A similar analysis, on a
comparable number of STUMPs, has been previously reported [4] identifying a genomic
index, based on array-CGH data, as a recurrence predictor. However, we did not find that
the genomic index is a recurrence predictor for our patients.
We found that the number of CNAs correlates with primary STUMPs and LMSs
prognosis. In fact, samples derived from patients with a worse prognosis displayed a
higher number of CNAs compared to the ones derived from patients with a good one.
In order to identify CNAs with a potential prognostic value, we selected the most
frequently shared CNAs between STUMP and LMS samples. Array-CGH data showed a
high number of gains and a very low number of losses in these lesions. Our hypothesis is
that genomic losses would be hidden due to a previous step of genome endoreduplication,
as we previously suggested [5]. The presence of polysomy for chromosomes 3, 7 and 17
detected by fluorescence in situ hybridization support this hypothesis (Figure S2).
It is already known that copy number gains or amplifications are associated with
protein overexpression in cancer. Eight samples (four STUMPs and four LMSs) shared gain
or amplification of PRKDC (DNA-Dependent Protein Kinase Catalytic Subunit). This gene
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is a key component of the non-homologous end joining pathway for DNA repair and its
overexpression and/or copy number gain have been observed in several cancer types,
such as lung cancer, liver cancer and colorectal cancer, and are associated with more
advanced tumor grade and poor survival [8,9]. Recently, its high expression has been
associated with poor survival in gastric cancer patients [10] and in both treated and
untreated breast cancer patients [11]. In our samples, copy number gain was not associated
with poor prognosis; however, it was not identified in leiomyomas. This makes it a very
interesting target.
MLL3 (Mixed Lineage Leukemia 3) copy number gain or amplification was shared
among seven samples (three STUMPs and four LMSs). Intriguingly, two STUMPs sub-
sequently relapsed and the third was a relapsed STUMP. Mutations of this gene were
reported in different tumors [12], but not in STUMP or leiomyosarcoma.
ROCK2 and CTSB gains or amplifications were shared among six samples (both
STUMPs and LMSs). ROCK2 (Rho associated coiled-coil containing protein kinase 2)
upregulation has been described in human glioblastoma CSCs [13], in gastric cancer [14],
as well as in ovarian cancer samples [15]. Moreover, ROCK2 expression level has been
associated with worse prognosis in osteosarcoma tissues [16]. CTSB (cathepsin-B) overex-
pression has been identified in several tumors with different effects on patient survival [17].
However, high expression of CTSB has been related to poor survival in glioblastoma
patients and involved in promoting temozolomide intrinsic resistance [18].
STAT2 has a well-known role in the anti-viral, immunomodulatory, anti-apoptotic
and anti-proliferative effects of IFN-I [19]. Moreover, its high expression in different
tumors, such as melanoma, colon adenocarcinoma, breast cancer and lung cancer, has been
associated with poor prognosis, highlighting it as a promising therapeutic target [20]. In our
samples, its gain/amplification was identified in one relapsing STUMP and its recurrence
and in three LMSs, both primary and relapsed.
Interestingly, three out of four relapsing STUMPs shared an amplification of the PUM2
gene. PUM2 is an RNA-binding protein involved in embryonic development, cell differen-
tiation and stem cell proliferation. Its role has also been reported in several tumors, such as
glioblastoma, where it was overexpressed and promoted cell proliferation [21], or breast
tumor, where it promoted the stemness of cancer cells [22].
We refined the analysis comparing only the relapsing STUMPs with LMSs, and we
found some shared CNAs. In particular, we observed a copy number gain in four samples
(one STUMP and three LMSs) involving STAG1 (Stromal Antigen 1). Its amplification
and overexpression in breast and ovarian cancer cell lines has been previously demon-
strated [23].
The same STUMP sample (the only relapsed in a LMS) shared RFC4 (Replication
Factor C Subunit 4) gain with three LMSs. Overexpression of RFC4 commonly occurs
in colorectal cancer and higher levels of RFC4 protein expression correlate with a worse
overall survival [24]. Moreover, its overexpression in tumor tissues predicted poor survival
in hepatocellular carcinoma and it was also considered a potential therapeutic target [25].
Finally, ELF2 (E74 Like ETS Transcription Factor 2) copy number gain was shared
among only three samples, but its role in tumorigenesis has been well described. In fact,
overexpression of ELF2 enhanced tumor cell proliferation [26] in nasopharyngeal carcinoma,
while its silencing had the opposite effect [27].
We previously identified the amplification of BCL2 gene in primitive STUMPs and
their corresponding relapsed tumors [5]. This observation has not been confirmed in
this enlarged cohort, where BCL2 amplification was observed in different samples (eight
STUMPs and five LMSs), not only the ones that relapsed. It is therefore clear that an
increase of analyzed cases is crucial for the validation of new targets. In this context,
we collected and examined 14 STUMPs, a significant number for this rare type of tumor.
Epigenomic modifications, such as DNA methylation, are an integral part of the molec-
ular determinants, contributing to malignancy [28]. For the first time in our knowledge,
we mapped out a methylation profile for this type of tumors. Considering the global
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DNA methylation data, an overall CGI hypomethylation of the STUMP that relapsed was
noticed compared to the other three samples. Although the analysis was performed on
few cases (two STUMPs and two LMSs), it is interesting that this finding is similar to the
one we previously published on three glioma stem cell lines [6]. This analogy could be
explained by a greater presence of cancer stem cells in STUMP4, which would justify the
worse prognosis with relapse and death of the patient.
In cancer, the role of promoter hypermethylation in silencing tumor suppressor genes
and its impact on tumor initiation, progression and prognosis are well known. Even though
DNA hypomethylation was the first epigenetic disruption in cancer [29], it took more
studies to define its implications in tumorigenesis leading to genomic instability [30], en-
hanced expression [31], loss of imprinting [32] and abnormal X-chromosome activation [33].
It is interesting to note that the total number of CNAs of STUMP4 is doubled compared
to its recurrence and threefold compared to the other STUMP, confirming the association
between DNA hypomethylation and genomic instability.
Our data showed a threefold of genes with unmethylated promoter CGIs compared to
the methylated ones, considering all four samples. As expected, no statistically significant
differences were highlighted by the Gene Ontology analysis comparing the four samples.
Conversely, significant differences for several categories emerged from the isolation of the
sample with a different profile of methylation (STUMP4), and the comparison with the other
three. This analysis highlighted specific signaling pathways that might be preferentially
activated in this tumor. The same conclusion emerged thanks to the comparison of the
primary sample with its recurrence, outlining a distinctive behavior of the sample with the
worst prognosis.
In conclusion, our data demonstrated a more similar genomic profile between STUMPs
and LMSs with some genes with a potential prognostic value. Despite the lack of an NGS-
based point mutations investigation, which would have given a complete picture of the
mutation burden (the landscape), and the number of samples being too small to draw
conclusions, the Gene Ontology analysis highlighted some cancer genes that could play a
pivotal role in the unexpected aggressive behavior in some of these tumors. These genes
could prove to be prognostic markers in the future. Finally, the methylation data appears
to be very promising, especially with regards to the divergent profile found in the sample
that relapsed, despite the analysis being restricted to only four samples.
4. Materials and Methods
4.1. Tumor Samples/Patients
A total of 23 uterine smooth muscle tumors: 3 leiomyomas, 14 STUMPs, 5 leiomyosar-
comas and 1 undifferentiated sarcoma, were collected from a total of 20 patients (Table 1).
Comitato Etico della provincia Monza e Brianza approval and written informed consent
was obtained. Patients were selected by a team of pathologists with high level of expertise
in the field of soft tissues gynecological neoplasms, supported by a team of gynecologic
oncologists with high level of expertise in soft tissue sarcoma.
In our case, we based the diagnosis of STUMP following the WHO indication: a uter-
ine SMT that cannot be diagnosed unequivocally as malignant (at least two of the fol-
lowing criteria: diffuse moderate-to-severe atypia, a mitotic count of at least 10 mitotic
figures/10 HPF, tumor cell necrosis, as defined by Bell et al. [34]) or clearly benign.
As far as we are concerned, all the specimens defined as STUMP had <10 mito-
sis/10 HPFs, but were not classified as benign because of the presence of tumor necrosis
even without atypia or additional histological parameters that may predict adverse outcome,
as reported by Gupta et al. [35] (briefly: remarkable atypia and borderline mitosis, atypi-
cal mitoses, epithelioid differentiation, vascular involvement, infiltrative/irregular margins).
4.2. Immunohistochemistry
Immunohistochemical staining was performed on FFPE (4% formalin) sections of
1-µm thickness. The entire pre-treatment process of deparaffinization, rehydration and
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epitope retrieval was performed using PT LINK (Dako, supplied by Agilent Technologies,
Santa Clara, CA, USA). Then the sections were placed into the Autostainer Link 48 with
the EnVision FLEX visualization system.
Estrogen receptor (ER), progesterone receptor (PgR), p16, p53, Ki67 (for mitotic activ-
ity) and other markers were evaluated (all antibodies were purchased from Dako, except for
p16 antibody that was from Gennova Scientific, Sevilla, Spain). For interpretation of im-
munohistochemical staining, the system proposed by Ip et al. [36] was adopted. In particu-
lar, the percentage of positive nuclei for ER, PgR and Ki67 and a scale of positivity (neg: no
staining, 1+: <33% of positive cells, 2+: 33–66% of positive cells, 3+: >66% of positive cells)
for p16, p53, myogenic markers (actin, desmin) and CD10 were reported in Table 1. For p16,
either strong nuclear or cytoplasmic staining or a combination, was considered positive.
For p53, only nuclear staining was considered positive.
4.3. DNA Extraction from FFPE Tissues
DNA extraction from Formalin-Fixed Paraffin-Embedded (FFPE) tissues was per-
formed by Invisorb® spin Tissue Mini Kit (Stratec Molecular GmbH, D-13125, Berlin,
Germany) using 10 µm slices from formaline-fixed paraffin embedded biopsies. All DNAs
were quantified by Nanodrop-1000 (ThermoFisher, Wien, Austria) and DNA integrity
was measured through agarose gel electrophoresis; generally all FFPE DNA appeared
partially fragmented.
4.4. Array Comparative Genomic Hybridization (Array-CGH)
Sample preparation, slide hybridization and analysis were performed using SurePrint
G3 Human CGH Microarray 8 × 60 K (Agilent Technologies, Santa Clara, CA, USA)
based on the UCSC Genome Browser hg18, NCBI build 36.1, March 2006 with 41Kb overall
median probe spacing (33 Kb in RefSeq genes), according to the manufacturer’s instructions
for FFPE samples. A control female DNA from a healthy female blood donor was used as
sex-match reference. This control DNA was validated by testing on CGH microarray using
as references available commercial European Male DNA NA-1289 and European Female
DNA NA-12878 (Coriell Institute, Camden, NJ, USA) and by self-hybridization. All the
samples were heat fragmented at 99 ◦C for 10 to 20 min and 250 ng of fragmented DNA per
sample were directly labelled by Genomic DNA ULS-labelling Kit (Agilent Technologies)
according to the protocol. ULS-labelling kit does not copy or amplify the input DNA, so
the yield after the labelling is the same as the input DNA. The arrays were scanned at 2 µm
resolution using the Agilent microarray scanner and analyzed using Feature Extraction
v10.7 and Agilent Genomic Workbench v5.0 softwares (Agilent Technologies, Santa Clara,
CA, USA). The Aberration Detection Method 2 (ADM-2) algorithm was used to compute
and assist the identification of aberrations in a given sample (threshold = 5.0), assigning a
statistical score based on the average quality weighted log ratio (DLRS) of the sample and
reference channels. ADM2 threshold filter selected at least three contiguous probes with an
average absolute value of the log2ratio change of 0.60 across the aberration in order to define
gains and losses. Additional abnormalities were manually noted when detected via visual
inspection of the experimental data points for each chromosome. The estimated percentage
of mosaicism was calculated using the formula determined by Cheung SW et al. [37].
4.5. MeDIP-Chip
Methylated DNA immunoprecipitation and chip hybridization were performed fol-
lowing the guidelines of Agilent Microarray Analysis of Methylated DNA Immunoprecipi-
tation Protocol (Version 1.0, Agilent Technologies, Santa Clara, CA, USA) as previously de-
scribed [6]. Briefly, purified genomic DNA was sonicated to obtain fragments of 200–600 bp
in size and 5 µg of sheared DNA was immunoprecipitated using 50 µl of pan-mouse IgG
Dynal magnetic beads (Life Technologies Italia, Monza, Italy) and 5 µg of 5-methylcytosine
antibody (Eurogenetec, Seraing, Belgium). MeDIPed DNA and reference DNA were puri-
fied and directly labelled with Cyanine 5- and Cyanine 3-dUTP nucleotides, respectively,
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using the SureTag DNA Labelling Kit (Agilent Technologies, Santa Clara, CA, USA). Cy5-
and Cy3-labelled samples were combined in a single mixture and hybridized onto a Human
CpG Island Microarray 1 × 244 K (Agilent Technologies, Santa Clara, CA, USA) for 40
h at 67 ◦C. Microarrays were scanned at 5 µm using an Agilent microarray scanner and
images analyzed with the Agilent Feature Extraction software v10.7. Data were analyzed by
means of the Agilent Genomic Workbench v5.0 software (Agilent Technologies, Santa Clara,
CA, USA). The full list of CpG islands (CGIs) analyzed is based on the UCSC Genome
Browser hg18, NCBI build 36.1, March 2006. Data were further analyzed according to the
methodological approach conceived by Dr. Ravid Straussman and colleagues in 2009 [38].
Briefly, probe z-scores for each CGI were averaged to obtain the Island Methylation Score
(IMS) and IMS distribution allowed threshold setting for determining the methylation
status of each CGI. CGIs resulted fully methylated (+1) or fully unmethylated (−1) or
undetermined (0). Undetermined CGIs were not considered for Gene Ontology analysis.
4.6. Bionformatic Analysis
The Gene Ontology analysis was performed using the GOstat software (http://gostat.
wehi.edu.au/ accessed on 21 May 2020 [39]) in order to identify the possible enrichment of
functional groups related to “biological process”, in a specific input list of genes. GOterms
were divided in cancer-relevant functional categories as previously described [6]. Analyzed
categories were: ‘cell cycle’, ‘cell death and apoptosis’, ‘response to stimulus’, ‘cytoskeleton
organization’, ‘cell signalling’, ‘development and morphogenesis’, ‘cell differentiation’,
‘immune response’, ‘cell motility’, ‘metabolism’, ‘transcription and gene expression’, ‘intra-
cellular transport’, ‘DNA repair and chromatin remodeling’.
GOstat analysis was also performed narrowing the GO hierarchy through the use of
‘biological_function’ as a keyword.
Supplementary Materials: The following are available online at https://www.mdpi.com/1422-006
7/22/4/1580/s1, Figure S1: Array-CGH results, Figure S2: Fluorescence in situ hybridization results,
Table S1: CNAs shared between STUMPs and LMSs, or STUMPs and LMs, Table S2: Methylation
status of gene involved in cell signaling pathway.
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